Evolus’ (EOLS) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Evolus (NASDAQ:EOLS) in a research report report published on Wednesday morning, Benzinga reports. They currently have a $27.00 price objective on the stock.

A number of other research analysts also recently weighed in on the company. Barclays upgraded Evolus from an equal weight rating to an overweight rating and lifted their price target for the company from $10.00 to $16.00 in a report on Monday, January 29th. Needham & Company LLC reaffirmed a buy rating and set a $22.00 target price on shares of Evolus in a research note on Wednesday.

Evolus Stock Down 1.2 %

Evolus stock traded down $0.16 during mid-day trading on Wednesday, hitting $13.10. The company’s stock had a trading volume of 47,784 shares, compared to its average volume of 626,498. The stock’s fifty day moving average price is $13.25 and its two-hundred day moving average price is $11.53. The stock has a market capitalization of $819.98 million, a P/E ratio of -12.17 and a beta of 1.47. Evolus has a twelve month low of $7.07 and a twelve month high of $15.43.

Evolus (NASDAQ:EOLS) last released its quarterly earnings results on Thursday, March 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.05). The firm had revenue of $61.00 million for the quarter, compared to analyst estimates of $61.14 million. Equities analysts expect that Evolus will post -0.51 earnings per share for the current year.

Insider Buying and Selling

In other Evolus news, CFO Sandra Beaver sold 5,672 shares of the business’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $13.92, for a total value of $78,954.24. Following the transaction, the chief financial officer now owns 154,201 shares in the company, valued at $2,146,477.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CFO Sandra Beaver sold 5,672 shares of Evolus stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $13.92, for a total value of $78,954.24. Following the completion of the sale, the chief financial officer now owns 154,201 shares of the company’s stock, valued at approximately $2,146,477.92. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider David Moatazedi sold 7,706 shares of the stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $13.08, for a total value of $100,794.48. Following the transaction, the insider now directly owns 792,416 shares in the company, valued at approximately $10,364,801.28. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 49,038 shares of company stock worth $674,232. Corporate insiders own 5.40% of the company’s stock.

Institutional Trading of Evolus

Several large investors have recently modified their holdings of EOLS. SG Americas Securities LLC acquired a new position in Evolus during the 3rd quarter worth $171,000. Bank of New York Mellon Corp lifted its position in shares of Evolus by 12.3% during the 3rd quarter. Bank of New York Mellon Corp now owns 164,020 shares of the company’s stock worth $1,499,000 after purchasing an additional 17,999 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Evolus by 13.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 12,345 shares of the company’s stock valued at $113,000 after purchasing an additional 1,484 shares during the period. Rice Hall James & Associates LLC grew its holdings in Evolus by 61.7% in the 3rd quarter. Rice Hall James & Associates LLC now owns 1,105,159 shares of the company’s stock valued at $10,101,000 after buying an additional 421,890 shares during the last quarter. Finally, Black Swift Group LLC bought a new position in Evolus in the 3rd quarter worth approximately $466,000. 90.69% of the stock is owned by institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.